← Leaderboards
Donald T Moir
Oscient Pharmaceuticals Corporation
$17,688,060
Attributed
$17,837,784
Total exposure
15
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2005–20$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$17,837,784 · 15
By mechanism
R44$6,172,730 · 2
R43$4,310,139 · 7
R01$3,168,838 · 1
R41$2,399,935 · 4
R42$1,786,142 · 1
Top collaborators
- Alejandro Pablo Heuck1 shared
Others in their field
Top investigators on “Inhibitor/Antagonist”
- John M Lachin · George Washington University$117,867,649
- David M Nathan · Massachusetts Institute Of Technology$117,867,649
- Randall J Bateman · Washington University$110,978,751
- David Heimbrook · Leidos Biomedical Research, Inc.$72,139,282
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Walter John Curran · Thomas Jefferson University$32,790,605
Research focus
Inhibitor/AntagonistStructurePseudomonas AeruginosaAntibioticsExhibitsBacteriaAnimal ModelLeadInfectionLibrariesPathogenPharmaceutical PreparationsBaseCellsAnti-Bacterial AgentsCytotoxicitySmall MoleculeProteinsIn VitroDrug ResistanceMedicalToxic EffectAntibiotic TherapyMediating
Grant awards (33)
Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa$299,449
R41 · FY2020 · AI · contact PI
Inhibitors of the viral nucleoprotein-polymerase co-factor interaction for human RSV and MPV therapy$284,808
R41 · FY2017 · AI · contact PI
Inhibitors of the viral nucleoprotein-polymerase co-factor interaction for human RSV and MPV therapy$300,000
R41 · FY2016 · AI · contact PI
Antibiotic potentiators maximizing the formation of open- channel OprF-type outer membrane porins$287,018
R43 · FY2016 · AI · contact PI
Validating targets in p. aeruginosa type III secretion using chemical probes$649,975
R01 · FY2015 · AI · contact PI
Antibiotic potentiators maximizing the formation of open- channel OprF-type outer membrane porins$282,826
R43 · FY2015 · AI · contact PI
Validating targets in p. aeruginosa type III secretion using chemical probes$851,764
R01 · FY2014 · AI · contact PI
Aminoglycoside potentiators for P. aeruginosa therapy$300,000
R43 · FY2014 · AI · contact PI
Inhibitors of isoprenoid synthesis for antibacterial therapy$300,000
R43 · FY2014 · AI · contact PI
Type III Secretion Inhibitors for Anti-Infective Therapy$978,562
R44 · FY2013 · AI · contact PI
Validating targets in p. aeruginosa type III secretion using chemical probes$804,173
R01 · FY2013 · AI · contact PI
Inhibitors of isoprenoid synthesis for antibacterial therapy$300,000
R43 · FY2013 · AI · contact PI
Aminoglycoside potentiators for P. aeruginosa therapy$300,000
R43 · FY2013 · AI · contact PI
Inhibitors of S. aureus bNOS for adjunctive therapy$290,500
R43 · FY2013 · AI · contact PI
Type III Secretion Inhibitors for Anti-Infective Therapy$979,998
R44 · FY2012 · AI · contact PI
Validating targets in p. aeruginosa type III secretion using chemical probes$862,926
R01 · FY2012 · AI · contact PI
Inhibitors of S. aureus bNOS for adjunctive therapy$290,500
R43 · FY2012 · AI · contact PI
Type III Secretion Inhibitors for Anti-Infective Therapy$1,000,000
R44 · FY2011 · AI · contact PI
DNA HELICASE AND PRIMASE INHIBITORS FOR BIODEFENSE$915,304
R42 · FY2010 · AI · contact PI
DNA HELICASE AND PRIMASE INHIBITORS FOR BIODEFENSE$870,838
R42 · FY2009 · AI · contact PI
Therapeutics targeting fatty acid synthesis in P. aeruginosa$292,209
R43 · FY2009 · AI · contact PI
Discovery of B. pseudomallei therapeutics for Biodefense$1,050,163
R44 · FY2008 · AI · contact PI
Therapeutics targeting fatty acid synthesis in P. aeruginosa$300,000
R43 · FY2008 · AI · contact PI
Discovery of B. pseudomallei therapeutics for Biodefense$1,170,128
R44 · FY2007 · AI · contact PI
Type III Secretion Inhibitors for Anti-Infective Therapy$314,826
R43 · FY2007 · AI · contact PI
Discovery of B. pseudomallei therapeutics for Biodefense$993,879
R44 · FY2006 · AI · contact PI
DNA helicase and primase inhibitors for biodefense$581,450
R41 · FY2006 · AI · contact PI
Type III Secretion Inhibitors for Anti-Infective Therapy$338,818
R43 · FY2006 · AI · contact PI
DNA helicase and primase inhibitors for biodefense$565,077
R41 · FY2005 · AI
Sensing Biowarfare Agents by Surface Enhanced Raman$369,151
R41 · FY2005 · AI
Discovery of B. pseudomallei Therapeutics for Biodefense$349,543
R43 · FY2004 · AI
Discovery of B. pseudomallei Therapeutics for Biodefense$308,156
R43 · FY2003 · AI
Discovery of B. pseudomallei Therapeutics for Biodefense$55,743
R43 · FY2003 · AI